In a comparison of two Medical Services stocks, Concentra Group (CON) emerges as the superior value option compared to Medpace (MEDP). CON holds a Zacks Rank of #2 (Buy) with improving earnings outlook and more attractive valuation metrics, including a forward P/E of 22.74 versus MEDP's 34.77, and a PEG ratio of 1.37 versus 2.72. CON also received a Value grade of B compared to MEDP's D grade.

Medpace (MEDP) closed down 1.64% and currently holds a Zacks Rank #3 (Hold) rating. The stock trades at a Forward P/E of 35.35, significantly above the industry average of 17.86, and a PEG ratio of 2.77 versus the industry average of 1.67. While earnings are expected to grow 15.28% next quarter and 14.79% for the full year, the premium valuation suggests limited upside potential in the near term.

Medpace stock declined 2.84% on October 6, 2026, underperforming the broader market gains. The company is expected to report earnings on October 21 with projected EPS of $4.45 (up 15.28% YoY) and revenue of $708.75 million (up 7.4% YoY). However, the stock trades at a premium valuation with a Forward P/E of 35.38 versus the industry average of 16.59, and holds a Zacks Rank of #3 (Hold).

Medpace (MEDP) closed at $622.11, up 1% and outperforming the S&P 500. The clinical development services provider is expected to report Q3 2026 earnings of $4.45 per share (up 15.28% YoY) with revenue of $708.75 million (up 7.4% YoY). However, the stock trades at a Forward P/E of 35.12, significantly above the industry average of 16.95, and carries a Zacks Rank #3 (Hold) rating with no recent estimate revisions.

Medpace (MEDP) closed at $624.20, up 1.94%, outperforming the S&P 500's 1.49% gain. The clinical development services provider has a Zacks Rank #3 (Hold) rating with projected EPS growth of 15.28% and revenue growth of 7.4% for the upcoming quarter. However, the stock trades at a Forward P/E of 34.91, significantly above the industry average of 17.31, and has a PEG ratio of 2.73 compared to the industry average of 1.48, suggesting premium valuation.

A comparison of two Medical Services sector stocks reveals that Concentra Group (CON) is more attractive to value investors than Medpace (MEDP). CON has a stronger Zacks Rank (#1 vs #2), lower valuation multiples (forward P/E of 20.95 vs 33.25, PEG ratio of 1.26 vs 2.60, and P/B ratio of 9.04 vs 37.52), and a better Value grade (B vs D), making it the superior option for value-focused investors.

A class action lawsuit has been filed against Medpace Holdings, Inc. on behalf of shareholders for alleged securities fraud. The lawsuit was triggered after Medpace reported a book-to-bill ratio of 1.04 on February 9, 2026, significantly below company guidance, causing the stock to plunge 15.9% to $446.05 per share. The class period covers April 22, 2025 through February 9, 2026.

Rosen Law Firm is notifying investors about multiple securities class action lawsuits. The primary case involves Medpace Holdings, with a June 8, 2026 deadline for lead plaintiff claims. The lawsuit alleges Medpace made false statements about backlog cancellation rates and provided misleading growth projections. Additional class actions are mentioned for Veritone, Inc. and Babcock & Wilcox Enterprises, Inc.

A class action lawsuit has been filed against Medpace Holdings, Inc. alleging that company executives made materially false and misleading statements regarding the book-to-bill ratio during the period from April 22, 2025 to February 9, 2026. The complaint claims defendants portrayed an overly optimistic ratio of approximately 1.15 despite contrary internal information, resulting in false statements about the company's business and financial prospects.

Rosen Law Firm is urging investors who purchased Veritone, Inc. securities between October 14, 2025 and April 14, 2026 to join a class action lawsuit before the July 20, 2026 lead plaintiff deadline. The lawsuit alleges that Veritone made false statements about its financial performance, inaccurately recorded revenue and costs, overstated assets, and maintained deficient internal controls, leading to required financial statement restatements.

Rosen Law Firm is notifying investors in Medpace Holdings, Upstart Holdings, and Babcock & Wilcox Enterprises of securities class action lawsuits. The firm alleges that Medpace made false statements about backlog cancellation rates and provided misleading growth projections. Investors with losses exceeding $100,000 are encouraged to secure counsel before the June 8, 2026 deadline to potentially serve as lead plaintiffs.

A class action securities fraud lawsuit has been filed against Medpace Holdings for allegedly making materially false statements about its business performance. The company missed its book-to-bill ratio guidance of 1.15, reporting only 1.04 due to record backlog cancellations, causing the stock to fall 15.9% on February 10, 2026. Investors who purchased shares between April 22, 2025 and February 9, 2026 can file a lead plaintiff motion by June 8, 2026.